Clinical Trials Logo

Lupus Erythematosus, Systemic clinical trials

View clinical trials related to Lupus Erythematosus, Systemic.

Filter by:

NCT ID: NCT04058028 Completed - Clinical trials for Systemic Lupus Erythematosus (SLE)

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

Start date: February 19, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE have ongoing disease activity despite treatment with standard of care therapies.

NCT ID: NCT03979976 Completed - Clinical trials for Systemic Lupus Erythematosus

Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus

Start date: March 2011
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this study was to evaluate the effect of ramipril on the endothelial function and on the number of endothelial progenitor cells (EPCs) in systemic lupus erythematosus (SLE) patients.

NCT ID: NCT03978520 Completed - Clinical trials for Systemic Lupus Erythematosus (SLE)

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

SLEek
Start date: July 25, 2019
Phase: Phase 2
Study type: Interventional

The main objective of this study was to evaluate the safety and efficacy of elsubrutinib, upadacitinib (UPA), and ABBV-599 (elsubrutinib/upadacitinib) High Dose and Low Dose combinations vs placebo for the treatment of signs and symptoms of Systemic Lupus Erythematosus (SLE) in participants with moderately to severely active SLE and to define doses for further development.

NCT ID: NCT03951259 Completed - Clinical trials for Systemic Lupus Erythematosus

Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Start date: July 24, 2019
Phase: Phase 2
Study type: Interventional

This is a single-center, randomized, double-blind, placebo-controlled, phase 2 study. The purpose of the study is to initially evaluate the safety and efficacy of SM934 combined with steroids compared to placebo in adult subjects with active systemic lupus erythematosus (SLE) over a 12-week period.

NCT ID: NCT03949426 Completed - Clinical trials for Systemic Lupus Erythematosus

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

Start date: May 1, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study to investigate the safety, tolerability and pharmacokinetics (PK) of KPG-818 in healthy male and female participants and the effect of food on the PK of KPG-818. The study will assist in identifying appropriate, well tolerated doses that can be administered in subsequent studies in healthy participants and participants with systemic lupus erythematosus (SLE).

NCT ID: NCT03942718 Completed - Clinical trials for Systemic Lupus Erythematosus

Systemic Lupus Erythematosus Exercise Program

SLEEP
Start date: March 21, 2018
Phase: N/A
Study type: Interventional

This pilot study is a randomized controlled trial to assess the effect of an individualized supervised exercise program in patients with systemic lupus erythematosus (SLE) compared to treatment-as-usual (TAU).

NCT ID: NCT03941184 Completed - Clinical trials for Rheumatoid Arthritis

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

Start date: January 1, 1995
Phase:
Study type: Observational

This case control study aims to determine whether spontaneous coronary artery dissection (SCAD) is associated with autoimmune diseases and to update the incidence of SCAD in a population-based cohort.

NCT ID: NCT03933943 Completed - Clinical trials for Lupus Erythematosus, Systemic

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

Start date: May 21, 2019
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to learn more about the safety of LY3361237 and any side effects that might be associated with it when given to participants with systemic lupus erythematosis (SLE). LY3361237 will be administered by injections just under the skin. The study will last up to 26 weeks and may include up to 17 visits to the study center.

NCT ID: NCT03933839 Completed - Clinical trials for Lupus Erythematosus, Systemic

Internet-Based Pain Coping Skills Training for Patients With Lupus

PainCOACH
Start date: May 20, 2019
Phase: N/A
Study type: Interventional

This is a pilot study of an automated, internet-based pain coping skills training (PCST) program, PainCOACH.

NCT ID: NCT03896373 Completed - Clinical trials for Lupus Erythematosus, Systemic

Role of the Neonatal Fc Receptor for IgG in the Pathophysiology of Lupus

RFPL
Start date: April 17, 2019
Phase:
Study type: Observational

This study evaluates the expression of the neonatal fc receptor (FcRn) in white blood cells and antigen-presenting cells (APC) in active lupus patients compared to inactive lupus patients and control to investigate if it's upregulated or not.